Canada Markets close in 2 hrs 41 mins

NervGen Pharma Corp. (NGEN.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
2.21000.0000 (0.00%)
As of 03:59PM EDT. Market open.
Full screen
Previous Close2.2100
Open2.1900
Bid2.1800 x 0
Ask2.2100 x 0
Day's Range2.1200 - 2.2700
52 Week Range1.2600 - 3.3300
Volume44,225
Avg. Volume44,863
Market Cap101.965M
Beta (5Y Monthly)1.89
PE Ratio (TTM)N/A
EPS (TTM)-0.3540
Earnings DateNov 18, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.53
  • Newsfile

    NervGen Hosting Panel Discussion with Leading Experts at the 2022 Annual Meeting of American Spinal Cord Injury Association (ASIA)

    Panel discussion will focus on the successful translation of NervGen's lead compound, NVG-291, from animals to humans Leading spinal cord injury experts on the panel include Drs. Jerry Silver, Monica Perez and James GuestNervGen will also present at the International Investment Forum Vancouver, British Columbia--(Newsfile Corp. - May 16, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company dedicated to developing a first-in-class

  • Newsfile

    NervGen Pharma Receives Approval to Proceed to the Final Dose Cohort in Phase 1 Clinical Trial of NVG-291 and Reports Q1 2022 Results

    Safety Review Committee approves proceeding to third and highest dose cohort in multiple ascending dose portion of clinical trial No serious or severe adverse events reported in second dose cohort with NVG-291Successful completion of the second cohort establishes a clear pathway to selecting a dose for upcoming Phase 1b/2 clinical trials Vancouver, British Columbia--(Newsfile Corp. - May 12, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical ...

  • Newsfile

    NervGen Pharma Appoints Craig Thompson to the Board of Directors

    30 years of industry experience from CEO of Nasdaq-listed biotech to Vice President, Marketing at PfizerExperience on 16 development stage products, 15 commercial stage products and numerous pre-clinical assets, in both start-up and large pharmaceutical companiesVancouver, British Columbia--(Newsfile Corp. - April 13, 2022) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQX: NGENF) ("NervGen" or the "Company"), a clinical stage biotech company developing a first-in-class neuroreparative drug to treat ne